In this HCPLive Peer Exchange, Dr. Natalie Cusano moderates a comprehensive discussion with Dr. Sara Lubitz, Dr. Dolores Shoback, Dr. Andrea Ferenczi, and Dr. Azarmindokht Khosravi on hypoparathyroidism, covering its multisystem burden, diagnostic challenges, treatment strategies, and evolving therapeutic landscape.
Welcome back to another HCPLive Peer Exchange series. In this episode titled "Hypoparathyroidism: Recognizing Signs, Symptoms, and Etiologies," moderator Dr. Natalie Cusano discusses hypoparathyroidism with Dr. Sara Lubitz, Dr. Dolores Shoback, Dr. Andrea Ferenczi, and Dr. Azarmindokht Khosravi.
In this episode, Dr. Cusano asks Dr. Lubitz to walk through the diagnostic approach to hypoparathyroidism, followed by Dr. Khosravi on establishing a multisystem baseline after diagnosis.
In this episode, Dr. Cusano asks Dr. Andrea Ferenczi to explain how hypoparathyroidism affects patients' quality of life and daily function, and whether the impact differs by etiology.
In this episode, Dr. Cusano asks Dr. Dolores Shoback to elaborate on the neurologic and neurocognitive complications of hypoparathyroidism, and then asks Dr. Sara Lubitz to discuss the cardiovascular risks.
In this episode, Dr. Cusano asks Dr. Azar Khosravi to discuss the musculoskeletal complications of hypoparathyroidism.
In this episode, Dr. Cusano asks Dr. Andrea Ferenczi to discuss the renal complications of chronic hypoparathyroidism.
In this episode, Dr. Cusano asks Dr. Dolores Shoback how she prioritizes and coordinates multisystem monitoring across the full range of hypoparathyroidism complications in clinical practice.
In this episode, Dr. Cusano asks Dr. Andrea Ferenczi to describe the goals of treatment in hypoparathyroidism and explain how management strategies differ by etiology, with particular attention to autosomal dominant hypocalcemia type 1 (ADH1).
In this episode, Dr. Cusano asks Dr. Khosravi to provide a comprehensive overview of the current treatment landscape for hypoparathyroidism, including both conventional therapy and novel options.
In this episode, Dr. Cusano asks Dr. Andrea Ferenczi to elaborate on the limitations of conventional therapy, the monitoring approach over time, and the factors that guide a transition to PTH replacement.
In this episode, Dr. Cusano asks Dr. Sara Lubitz to explain the mechanism of action and administration of palopegteriparatide, then turns to Dr. Dolores Shoback for a review of long-term clinical trial data and patient-reported outcomes.
In this episode, Dr. Cusano asks Dr. Sara Lubitz to discuss eneboparatide, an emerging PTH-1 receptor agonist for hypoparathyroidism, and then asks Dr. Dolores Shoback to compare the renal outcomes seen across PTH replacement therapies in clinical trials.
In this episode, Dr. Cusano asks Dr. Khosravi to explain how multisystem complications beyond renal disease factor into treatment selection and monitoring in hypoparathyroidism.
In this episode, Dr. Cusano asks Dr. Sara Lubitz to address management of hypoparathyroidism in pregnant and postpartum patients.
In this episode, Dr. Cusano asks Dr. Andrea Ferenczi to describe how hypoparathyroidism management must be adapted for special populations, including children, older adults, and those with significant comorbidities.
In this episode, Dr. Cusano asks Dr. Khosravi to identify the most significant unmet needs remaining in the current treatment landscape for hypoparathyroidism.
In this episode, Dr. Cusano asks Dr. Khosravi to identify the most significant unmet needs remaining in the current treatment landscape for hypoparathyroidism.
In this episode, Dr. Cusano asks Dr. Andrea Ferenczi to walk through preoperative risk identification, counseling, and postoperative management for patients undergoing thyroid or parathyroid surgery at risk for developing hypoparathyroidism.
In this final episode, Dr. Cusano asks Dr. Dolores Shoback how she tailors communication for patients who are not meeting treatment goals, experiencing complications, or struggling with the burden of long-term disease management.
